Social Behavior – Page 3

Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development Progress

2 months ago talkbio0Tagged biofilm-driven chronic respiratory disease, Brendan Doran, Clarametyx Biosciences, corporate development, executive promotions, Leadership, pipeline development, Steve St. Onge, Team

Clarametyx Biosciences; leadership team; executive promotions; pipeline development; corporate development; Steve St. Onge; Brendan Doran; immune-enabling therapies; biofilm-driven chronic respiratory disease

Ex-FDA Leaders Launch Canal Row Advisors, Offer Insights on Agency’s Challenges and Direction

2 months ago talkbio0Tagged Biological Science Disciplines, Canal Row Advisors, innovation, Leadership, Michael Rogers, Policy, public health medicine (field), reform, regulatory consulting, regulatory strategy, United States Food and Drug Administration

Canal Row Advisors; FDA leadership; regulatory consulting; Michael Rogers; Hilary Marston; life sciences; regulatory strategy; public health; FDA reform; innovation policy

Bicycle Health Grows Leadership Team to Expand Access for Justice-Involved Populations

2 months ago talkbio0Tagged Andy Thomas, Bicycle Health, Business Development, Criminal Justice, executive team, Leadership, Opioid Use Disorder, Steve Tomlin, virtual care

Bicycle Health; Leadership team; Executive team; Steve Tomlin; Business development; Criminal justice; Opioid use disorder; Virtual care; Manu Kuppalli; Andy Thomas

Somatix Readies Market Launch of First-of-its-Kind Wearable Medication Compliance Feature

2 months ago talkbio0Tagged Adherence To Medication Regime, AI-enabled, Detection, digital health, Gestures, partnering with, Presenile dementia, Preventive monitoring, Remote, Roche (company), SafeBeing platform, Somatix, Wearable Electronic Devices

Somatix; wearable technology; medication compliance; AI-enabled; gesture detection; remote patient monitoring; SafeBeing platform; dementia; partnering with Roche; digital health

Recent Moves in Biotech Leadership

2 months ago talkbio0Tagged biotech, eli lilly, Leadership, Moderna, Peter Marks

Biotech; Leadership; Moderna; Eli Lilly; Peter Marks

The 5 Most Powerful Women in Biopharma: 2025 News & Key Figures

2 months ago talkbio0Tagged Belén, Biopharma, CEO, Garijo, Leadership, Reshma Kewalramani, Sarah Boyce, Woman, Women, Yvonne Greenstreet

powerful women; biopharma; female CEO; Reshma Kewalramani; Yvonne Greenstreet; Sarah Boyce; Emma Walmsley; Belén Garijo; leadership

Novartis Receives FDA Approval for Rhapsido: First Oral BTK Inhibitor for Chronic Hives

2 months ago talkbio0Tagged Approved, Bruton 's tyrosine kinase inhibitor, BTKi, chronic hives, Chronic Spontaneous Urticaria, competition, Immunology, Novartis, Oral Therapy, remibrutinib, Rhapsido, United States Food and Drug Administration

Novartis; Rhapsido; FDA approval; Bruton’s tyrosine kinase inhibitor (BTKi); remibrutinib; chronic spontaneous urticaria (CSU); chronic hives; immunology; oral therapy; competition

Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion

3 months ago talkbio0Tagged Autoimmune Diseases, Collaboration, Drug Discovery, Immunology, molecular glue degraders, Monte Rosa Therapeutics, Novartis, QuEEN, royalties, upfront payment

Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration

Novartis Expands Degrader-Focused Collaboration with Monte Rosa Through Major Molecular Glue Deal

3 months ago talkbio0Tagged AI/ML-enabled product, Collaboration, Drug Discovery, engine, immune-mediated diseases, milestone payments, molecular glue degraders, Monte Rosa Therapeutics, MRT-6160, Novartis, VAV1 protein

Novartis; Monte Rosa Therapeutics; molecular glue degraders; MRT-6160; VAV1 protein; immune-mediated diseases; drug discovery; collaboration; milestone payments; AI/ML-enabled product engine

Eli Lilly Loses Appeal to Overturn $183.7 Million Medicaid Rebate Judgment

3 months ago talkbio0Tagged appeal, Circuit, court, drug price, eli lilly, False Claims Act, Fraud, judgment, Medicaid, Positive

Eli Lilly; Medicaid; rebate; court ruling; False Claims Act; drug pricing; whistleblower; 7th Circuit Court of Appeals; fraud; $183.7 million judgment